Multi-target drug treatment has become popular as a substitute for traditional monotherapy.
Monotherapy can lead to resistance and side effects. Multi-target drug discovery is gaining
importance as data on bioactivity becomes more abundant. The design of multi-target drugs is expected
to be an important development in the pharmaceutical industry in the near future. This review
presents multi-target compounds against trypanosomatid parasites (Trypanosoma cruzi, T.
brucei, and Leishmania sp.) and tuberculosis (Mycobacterium tuberculosis), which mainly affect
populations in socioeconomically unfavorable conditions. The article analyzes the studies, including
their chemical structures, viral strains, and molecular docking studies, when available. The objective
of this review is to establish a foundation for designing new multi-target inhibitors for these
diseases.